Moderna says experimental Covid vaccine 94.5% effective
Its interim analysis is based on 95 infections among trial participants who received either a placebo or the vaccine
Tue, Nov 17, 2020 - 5:50 AM
A key advantage of Moderna's vaccine is that it does not need ultra-cold storage like Pfizer's, making it easier to distribute. It is stable at standard refrigerator temperatures of 2-8 deg Celsius for 30 days.
MODERNA Inc said on Monday its experimental vaccine was 94.5 per cent effective in preventing Covid-19 based on interim data from a late-stage clinical trial, becoming the second US company in a week to report results that far exceed expectations.